In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...